March 23, 2023–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor” (clinicaltrials.gov NCT05540626), demonstrated that adding TAPS therapy to […]
More Support Available for Students with ET; We Can Weather ET Together; Study Documents Efficacy of Cala Trio; Clinical Trials Need You
Cala Trio continues to be an effective therapy for managing essential tremor, according to a recently released study by Cala Health. Liana Hennum, head of health economics outcomes research for Cala, talks about other positive outcomes revealed in this study.
BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, a bioelectronic medicine company developing wearable therapies for chronic disease, announces two validating pieces of news for the non-invasive prescription therapy for essential tremor (ET), Cala Trio™. Real-world evidence of a Veteran Affairs (VA) patient population presented at The International Parkinson and Movement Disorder Society (MDS) 2021 virtual congress on September 15 showcases Cala […]
BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today reported data demonstrating the increasing prevalence of essential tremor (ET) from 2010 to 2018; a high rate of depression and anxiety in patients with ET; and the safety and efficacy of Cala Trio when used in a real-world setting […]
It’s a watch-like device that stimulates nerves in the wrist to interrupt, and therefore, calm tremors in the hands. Listen to this conversation about the Cala Trio from Cala Health CEO Renee Ryan.
Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its FDA-cleared Cala Trio device reported a reduction in hand tremors.